Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 2-36 (IGKV2-36) is a member of the immunoglobulin kappa light chain variable region gene family located at chromosome 2p11.2[3][4]. Immunoglobulin variable region genes encode the antigen recognition portions of antibodies, generated through a process known as V(D)J recombination in developing B cells. The product of the IGKV2-36 gene, if expressed, would encode a variable (V) region that combines with a joining (J) region to contribute to antigen specificity. However, IGKV2-36 is mainly annotated as a pseudogene, meaning it is not generally productive in constructing functional immunoglobulin light chains[1][4]. The immunoglobulin variable region gene repertoire is highly diverse and underpins the adaptive immune system's ability to recognize a vast array of antigens[2][3]. IGKV2-36 does not itself act as a typical therapeutic target; rather, it is one of many gene segments involved in generating antibody diversity. Some immunoglobulin variable genes can occasionally be implicated in autoimmunity or lymphoid cancers through abnormal rearrangements, but IGKV2-36 itself is not specifically associated with such roles in the literature available. Key points: - IGKV2-36 is not considered a therapeutic target. - It does not code for a druggable protein or classical receptor/enzymatic target. - Its main function (shared with other V genes) is immune repertoire diversity, but it is a pseudogene in most references, so it does not produce a functional protein[1][4].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 2-36 (IGKV2-36).